Samaritan Expands Georgetown University Collaboration Strengthening and Enhancing Technology Pipeline

		SAMARITAN PHARMACEUTICALS CORPORATE LOGO Samaritan Pharmaceuticals, in collaboration with Georgetown University, develops and strives to commercialize scientific breakthrough innovations for: Alzheimer's (AD) Drugs, to inhibit glucocorticoid-mediated neurotoxicity, an Animal Model to test AD drugs, an AD Diagnostic; a Breast Cancer Diagnostic; a peptide to bind Cholesterol and a late stage Phase II statistically significant HIV drug. Samaritan's patented pipeline is built on a, cholesterol-metabolism and glucocorticoid-biosynthesis, technology platform which is scientifically considered to be a successful therapeutic approach. (PRNewsFoto)[AS] LAS VEGAS, NV USA

LAS VEGAS, April 8 /PRNewswire-FirstCall/ -- Samaritan Pharmaceuticals Inc. (OTC Bulletin Board: SPHC) and Samaritan Research Labs, Georgetown University, announced today that it has strengthened its scientific technology pipeline by expanding its Georgetown University seven year Sponsored Research Agreement with an additional financial commitment this year. These funds shall be used by Samaritan Laboratories/Georgetown to screen for additional new drug compounds, their binding capabilities to specific receptors and their direct effects on mitochondrial function. Mitochondria are the key to life and death. Quite possibly, the process of aging itself may be intimately linked to mitochondria. A sampling of some major health disorders where mitochondrial dysfunction may be linked to large segments of a diseased population are Alzheimer's, Lou Gehrig's, Cancer, Heart disease, Parkinson's and Type II Diabetes. Dr. Janet Greeson, CEO of Samaritan Pharmaceuticals, stated, "The future holds great promise for mitochondrial research. This is significant for Samaritan, in that, we expect new approaches and or drugs to flow from this newfound research. Not unlike Samaritan, most companies are in a rush to squeeze costs but we feel with additional funds to expand our technology in mitochondrial research, we will be able to deliver on our growth for tomorrow." (Photo: http://www.newscom.com/cgi-bin/prnh/20030129/SPHCLOGO ) About Samaritan Pharmaceuticals Samaritan Pharmaceuticals is a biopharmaceutical company that discovers, develops and commercializes breakthrough scientific innovation, in collaboration with Georgetown University. Samaritan is primarily focused on the development of new and novel therapies for Alzheimer's, Cancer, Cholesterol Reduction and HIV. The science, that separates Samaritan's technology pipeline include: positive "significant" HIV data for Phase II; an Alzheimer's Animal (rat) model to test new drugs; an Alzheimer's (Predictor) Diagnostic and Breast Cancer Diagnostic; a Peptide to bind cholesterol; and new neuroprotective compounds for memory loss. Disclaimer The company disclaims any information that is created by an outside party and endorses only information that is communicated by its press releases, filings and Web site. This news release contains forward-looking statements that reflect management's current beliefs about the potential for its drug candidates, science and technology. However, as with any biopharmaceutical under development, there are significant risks and uncertainties in the process of development and regulatory review. There are no guarantees that products will prove to be commercially successful. For additional information about the factors that affect the company's business, please read the company's latest Form 10-K filed April 26, 2002. The company undertakes no duty to update forward-looking statements. Contact: Samaritan Pharmaceuticals, Inc., 702/735-7001, Fax 702/737-7016 Gene Boyle, Business Development, Email GeneBoyle@aol.com Doug Bessert, Investor Relations, Email DougBessert@aol.com To receive future press releases and newsletters automatically, or for more information, visit our Web site at http://www.samaritanpharmaceuticals.com .